drugset / Trial / NCT01049685

Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy

NCT01049685

Phase 4 Unknown 36 enrolled UPECLIN HC FM Botucatu Unesp
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Retrospective longitudinal cohort study with 36 HIV naïve-treatment patients, who started therapy with lopinavir/ritonavir or efavirenz (LPV/r or EFZ), follow-up of 36 months. Primary endpoint: virological success (HIV RNA \<50 copies/mL) in the first six months and at the end of the study.

Timeline

Start
2006-08
Primary completion
2009-12
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Efavirenz Other / unclassified 1 unknown
Comparator Lopinavir/ritonavir Unknown 2 unknown